Calcilytics: Antagonists of the calcium-sensing receptor for the treatment of osteoporosis

Future Medicinal Chemistry

Volumn 3, Issue 5, 2011, Pages 535-547

  Widler, Leo ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIAMINOCYCLOHEXANE DERIVATIVE; 2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; ANABOLIC AGENT; ATF 936; AXT 914; BA 058; CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR ANTAGONIST; CALHEX 231; CINACALCET; JTT 305; NPS 53574; PARATHYROID HORMONE; PARATHYROID HORMONE[1-31][27 LEUCINE] AMIDE 22,26 AMIDE; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[1-36]; PLACEBO; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLIN 2 ONE DERIVATIVE; QUINAZOLIN 4 ONE DERIVATIVE; QUINAZOLINE DERIVATIVE; RECOMBINANT PARATHYROID HORMONE; RONACALERET; SB 222338; SB 423562; TECALCET; UNCLASSIFIED DRUG;

BONE DENSITY; BONE STRENGTH; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; FRAGILITY FRACTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; IC 50; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OSTEOSARCOMA; PARATHYROID HORMONE RELEASE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE AND BONES; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OSTEOPOROSIS; PARATHYROID HORMONE; RECEPTORS, CALCIUM-SENSING;

EID: 79955631110     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.11.17     Document Type: Review

References (89)

1. Berry SD, Kiel DP, Donaldson MG et al. Application of the National Osteoporosis Foundation guidelines to postmenopausal women and men: the Framingham osteoporosis study. Osteoporosis Int. 21, 53-60 (2010).
2. Ray NF, Chan JK, Thamer M, Melton LJ. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12, 24-35 (1997).
3. Tarantino U, Cannata G, Lecce D, Celi M, Cerocchi I, Lundusi R. Incidence of fragility fractures. Aging Clin. Exp. Res. 19(Suppl. 4), 7-11 (2007).
4. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40, 1434-1446 (2007). (Pubitemid 46756429)
5. Russell RG, Espina B, Hulley P. Bone biology and the pathogenesis of osteoporosis. Curr. Opin. Rheumatol. 18(Suppl. 1), S3-S10 (2006). (Pubitemid 44289183)
6. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905-916 (2007).
7. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81 (2005). (Pubitemid 40193486)
8. Neer RM, Arnaud DC, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1341 (2001).
9. File E, Deal D. Clinical update on teriparatide. Curr. Rheumatol. Reports 11, 169-176 (2009).
10. Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs 68, 2709-2737 (2008).
11. Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am. J. Health Syst. Pharm. 65, 532-539 (2008). (Pubitemid 351429714)
12. Horowitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88, 569-575 (2003). (Pubitemid 36207792)
13. O?Dea L, Lyttle CR, Rosen CJ. BA058, a novel analog of human parathyroid hormone-related peptide (PTHrP), induces evidence of bone formation without evidence of bone resorption over 7 days of exposure. Presented at: The 89th Annual Meeting of the Endocrine Society, Abstract P2-137. Toronto, ON, Canada, 2-5 June 2007.
14. Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr. Opin. Pharmacol. 2, 338-344 (2002). (Pubitemid 34594378)
15. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv. 2, 993-1002 (2005). (Pubitemid 41701199)
16. Tashjian AH, Goltzman D. On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J. Bone Miner. Res. 23, 803-811 (2008). (Pubitemid 351768798)
17. Trivedi R, Mitah A, Chattopadhyay N. Recent updates on the calcium-sensing receptor as a drug target. Curr. Med. Chem. 15, 178-186 (2008). (Pubitemid 351234621)
18. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell. Biochem. 45, 139-165 (2007).
19. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocrine Rev. 14, 690-709 (1993). (Pubitemid 24016657)
20. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab. 15, 60-65 (2004). (Pubitemid 38253007)
21. Loitnun S, Sibonga J, Turner R. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 17, 29-36 (2002). (Pubitemid 34311421)
22. Frolik CA, Black EC, Cain RL et al. Anabolic and catabolic effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33, 372-379 (2003). (Pubitemid 37103254)
23. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol. Metab. 21, 237-244 (2010).
24. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch. Biochem. Biophys. 473, 218-224 (2008).
25. Poole KE, Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr. Opin. Pharmacol. 5, 612-617 (2005). (Pubitemid 41614461)
26. Messa P, Alfieri C, Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin. Drug Metabol. Toxicol. 4, 1551-1560 (2008).
27. Harrington P, Fotsch C. Calcium sensing receptor activators: calcimimetics. Curr. Med. Chem. 14, 3027-3034 (2007). (Pubitemid 350226971)
28. Nemeth EF. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol. 29, 15-21 (2002). (Pubitemid 34965743)
29. Nemeth EF. Anabolic therapy for osteoporosis: calcilytics. Bonekey Osteovision 5(6), 196-208 (2008).
30. Nemeth EF. Drugs acting on the calcium receptor. In: Principles of Bone Biology (3rd Edition). Bilezikian JP, Raisz LG, Martin TJ (Eds). Elsevier, San Diego, CA, USA 1711-1735 (2008).
31. Trivedi R, Mithal A, Chattopadhyay N. Pharmacological manipulation of calcium-sensing receptor: prospect as anabolic therapy for postmenopausal osteoporosis. Drugs Fut. 34, 803-809 (2009).
32. Allen JG, Fotsch C, Babij P. Emerging targets in osteoporosis disease modification. J. Med. Chem. 53, 4332-4353 (2010).
33. Marquis RW, Lago AM, Callahan JF et al. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem. 52, 3982-3993 (2009).
34. Gowen M, Stroup GB, Dodds RA et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. 105, 1595-1604 (2000). (Pubitemid 30390310)
35. Nemeth EF, Delmar EG, Heaton WL et al. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299, 323-331 (2001). (Pubitemid 32905150)
36. Marquis RW, Lago AM, Callahan JF et al. Antagonists of the calcium receptor II. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem. 52, 6599-6605 (2009).
37. Kumar S, Matheny CJ, Hoffman SJ et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 46, 534-542 (2010).
38. Fitzpatrick LA, Brennan E, Kumar S et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J. Bone Miner. Res. 23(Suppl. 50), (2008).
39. Glover SJ, Eastell R, McCloskey EV et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45, 1053 (2009).
40. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized oseoporotic patients. J. Clin. Endocrinol. Metab. 77, 1535-1539 (1993). (Pubitemid 24000909)
41. Fitzpatrick L, Dabrowski C, Cicconetti G et al. Ronacaleret, a calcium-sensing receptor antagonist: results of a 1 year double-blind, placebo-controlled, dose ranging phase II study. J. Bone Miner. Res. 24(Suppl. 1), Abstract 1130 (2009).
42. Shinagawa Y, Inoue T, Hirata K et al. New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 20, 3809-3813 (2010).
43. Shinagawa Y, Inoue T, Katsushima T et al. Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone. ACS Med. Chem. Lett. DOI: 10.1021/ml100268k (2010) (Epub ahead of print).
44. Fukumoto S, Nakamura T, Nishizawa Y, Hayashi M, Matsumoto R. JTT-305 shows promise for the treatment of hypocalcemia and osteoporosis. J. Bone Miner. Res. 24 (Suppl. 1), Abstract 1131 (2009).
45. Balan G, Bauman J, Bhattacharya S et al. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg. Med. Chem. 19, 3328-3332 (2009).
46. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev. 20, 58-101 (2000). (Pubitemid 30027561)
47. Southers JA, Bauman JN, Price DA et al. Metabolism-guided design of short-acting calcium-sensing receptor antagonists. ACS Med. Chem. Lett. 1, 219-223 (2010).
48. Yang W, Wang Y, Roborge JY, Ma Z et al. Discovery and structure-activity relationships of 2-benzlypyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 15, 1225-1228 (2005). (Pubitemid 40458678)
49. Gavai AV, Vaz RJ, Mikkilineni AB et al. Discovery of novel 1-arylmethylpyrrolidin-2- ylethanolamines as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 15, 5478-5482 (2005). (Pubitemid 41562974)
50. Kessler A, Faure H, Roussanne MC et al. N1-arylsulfonyl-N2-(1-(1- naphthyl)ethyl)-1,2- diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem 4, 1131-1136 (2004). (Pubitemid 39257035)
51. Kessler A, Faure H, Petrel C et al. N1- Benzoyl-N2-[1-(1-naphthyl)ethyl]- trans-1,2- diaminocyclohexanes: development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J. Med. Chem. 49, 5119-5128 (2006). (Pubitemid 44260208)
52. Yang W, Ruan Z, Wang Y et al. Discovery and structure-activity relationships of trisubstituted pyrimidines/pyridines as novel calcium-sensing receptor antagonists. J. Med. Chem. 52, 1204-1208 (2009).
53. Arey BJ, Seethala R, Ma Z et al. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology 146, 2015-2022 (2005). (Pubitemid 40396912)
54. Shcherbakova I, Balandrin MF, Fox J et al. 3H-quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 15, 1557-1560 (2005). (Pubitemid 40312528)
55. Kalgutkar AS, Griffith DA, Ryder T et al. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5- (trifluoromehtyl) pyrido[4,3-d]pyrimidin-4(3H)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. Chem. Res. Toxicol. 23, 1115-1126 (2010).
56. Shcherbakova I, Huang G, Geoffroy OJ et al. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg. Med. Chem. Lett. 15, 2537-2540 (2005). (Pubitemid 40614985)
57. Didiuk MT, Griffith DA, Benbow JW et al. Short-acting 5-(trifluoromethyl)pyrido[4,3-d] pyrimidin-4(3H)-one derivatives as orally -active calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 19, 4555-4559 (2009).
58. Coombs RV, Danna RP, Denzer M et al. Synthesis and antiinflammatory activity of 1-alkyl-4-aryl-2(1H)-quinazolinones and quinazolinethiones. J. Med. Chem. 16, 1237-1245 (1973).
59. Houlihan WJ, Cooke G, Van Bochoven R, Perrine J, Takesue EI, Jukniewicz EJ. Anti-inflammatory properties of 8-aryl-5- isopropyl-2H-1,3-dioxolo[4,5-g] quinazolin- 6(5H)-ones and -thiones. J. Med. Chem. 25, 1110-1113 (1982).
60. Perrine JW, Houlihan WJ, Takesue EI. Antiinflammatory and other pharmacodynamic properties of five members of the 4-aryl-1-isopropyl-2(1H)- quinazolinone series. Arzneimittelforschung 34(8), 879-885 (1984). (Pubitemid 14099913)
61. Widler L, Altmann E, Beerli R et al. 1-alkyl-4-phenyl-6-alkoxy-1H- quinazoline-2- ones: a novel series of potent calcium-sensing receptor antagonists. J. Med. Chem. 53, 2250-2263 (2010).
62. John M, Widler L, Gamse R et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone (In Press).
63. Widler L, Gamse R, Seuwen K et al. A novel calcium-sensing receptor antagonist leads to dose-dependent transient release of parathyroid hormone after oral administration to healthy volunteers - an initial proof-of-concept for a potential new class of anabolic osteoporosis therapeutics. J. Bone Miner. Res. 23(Suppl. 49) (2008).
64. John M, Harfst E, Loeffler J et al. A 4-week study of AXT914, a novel calcilytic compound for oral bone anabolic osteoporosis therapy, in postmenopausal women. J. Bone Miner. Res. 25(Suppl. 1), S332 (2010).
65. Gerspacher M, Altmann E, Beerli R et al. Penta-substituted benzimidazoles as potent antagonists of the calcium sensing receptor (CaSR-antagonists). Bioorg. Med. Chem. Lett. 20, 5161-5164 (2010).
66. Petrel C, Kessler A, Mashlah F et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. J. Biol. Chem. 278, 49487-49494 (2003).
67. Petrel C, Kessler A, Dauban P, Dodd RH, Rogan D, Ruat M. Positive and negative allosteric modulators of the Ca2+-sensing receptor. J. Biol. Chem. 279, 18990-18997 (2004).
68. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279, 7254-7263 (2004). (Pubitemid 38248875)
69. Bu L, Michino M, Wolf RM, Brooks CL. Improved model building and assessment of the calcium-sensing receptor transmembrane domain. Proteins 71, 215-226 (2008). (Pubitemid 351358605)
70. Hu J, Jiang J, Costanzi S et al. A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J. Biol. Chem. 281, 21558-21565 (2006). (Pubitemid 44115492)
71. Magno AL, Ward BK, Ratajczak T. The calcium-sensing receptor: a molecular perspective. Endoc. Rev. 32(1), 3-30 (2010).
72. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat.Rev. Endocrinol. 3, 122-133 (2007). (Pubitemid 46146965)
73. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathopyhsiology. Clin. Rev. Clin. Lab. Sci. 42, 35-70 (2005). (Pubitemid 41656709)
74. Geibel JP, Hebert SC. The functions and roles of the extracellular Ca2+-sensing receptor along the gastrointestinal tract. Annu. Rev. Physiol. 71, 205-217 (2009).
75. Ba J, Friedman PA. Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium 35, 229-237 (2004). (Pubitemid 38292366)
76. Weston AH, Absi M, Ward DT et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells. Circ. Res. 97, 391-398 (2005). (Pubitemid 41216144)
77. Chakravarti B, Dwivedi SKD, Mithal A, Chattopadhyay N. Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine 35, 271-284 (2009).
78. Rodland KD. The role of the calcium-sensing receptor in cancer. Cell Calcium 35, 291-295 (2004). (Pubitemid 38292373)
79. Bandyopadhyay S, Tfelt-Hansen J, Chattopadhyay N. Diverse roles of extracellular calcium-sensing receptor in the central nervous system. J. Neurosci. Res. 88, 2073-2082 (2010).
80. Brown EM. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol. Metab. Clin. North Am. 29, 503-523 (2000).
81. Smithkline Beecham Co. WO2010055631 (2009).
82. Japan Tobacco Inc. WO0214259 (2002).
83. Japan Tobacco Inc. WO2004094362 (2004).
84. Japan Tobacco Inc. WO2004106280 (2004).
85. Daiichi Sankyo Co. WO2010074089 (2010).
86. Asahi Kasai Pharma Corp. WO2009148052 (2009).
87. Novartis AG. WO2008107390 (2008).
88. Novartis AG WO2007020046 (2007).
89. De Lano WL. The PyMol Molecular Graphics System, Version 1.0r2. DeLano Scientific LLC. San Carlos, CA, USA. www.pymol.org